JP2002522388A - 性機能障害の治療のためのピリジノン - Google Patents

性機能障害の治療のためのピリジノン

Info

Publication number
JP2002522388A
JP2002522388A JP2000563280A JP2000563280A JP2002522388A JP 2002522388 A JP2002522388 A JP 2002522388A JP 2000563280 A JP2000563280 A JP 2000563280A JP 2000563280 A JP2000563280 A JP 2000563280A JP 2002522388 A JP2002522388 A JP 2002522388A
Authority
JP
Japan
Prior art keywords
methyl
halo
lower alkyl
hydrogen
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000563280A
Other languages
English (en)
Japanese (ja)
Inventor
マノヴィッツ，ナイル，アール．
オブライアン，ロバート，エー．
モーガン，ヒュー，イー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Corp
Original Assignee
BASF Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF Corp filed Critical BASF Corp
Publication of JP2002522388A publication Critical patent/JP2002522388A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2000563280A 1998-08-03 1999-07-31 性機能障害の治療のためのピリジノン Pending JP2002522388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9506098P 1998-08-03 1998-08-03
US60/095,060 1998-08-03
PCT/EP1999/005544 WO2000007595A1 (fr) 1998-08-03 1999-07-31 Utilisation de pyridinones pour traiter les dysfonctionnements sexuels

Publications (1)

Publication Number Publication Date
JP2002522388A true JP2002522388A (ja) 2002-07-23

Family

ID=22249125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000563280A Pending JP2002522388A (ja) 1998-08-03 1999-07-31 性機能障害の治療のためのピリジノン

Country Status (5)

Country Link
EP (1) EP1107759A1 (fr)
JP (1) JP2002522388A (fr)
AU (1) AU5509099A (fr)
CA (1) CA2339484A1 (fr)
WO (1) WO2000007595A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541487B1 (en) * 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
CA2319542C (fr) * 1998-05-01 2005-07-12 Rt Alamo Ventures, Inc. Traitement des troubles de la sexualite chez certains groupes de patients
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
EP1355647A2 (fr) * 2001-01-26 2003-10-29 R.T. Alamo Ventures I, LLC Traitement de troubles sexuels et de maladie cardio-vasculaire avec des enantiomeres quinolinone
WO2003020728A1 (fr) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company Agents antiviraux a base de 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
AR038294A1 (es) * 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193167A (en) * 1979-03-27 1984-08-24 Boots Co Plc Quinoline derivatives and pharmaceutical compositions
EP0172004B1 (fr) * 1984-08-15 1990-03-21 The Boots Company PLC Quinolinones, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8515209D0 (en) * 1985-06-15 1985-07-17 Boots Co Plc Therapeutic agents
GB8515207D0 (en) * 1985-06-15 1985-07-17 Boots Co Plc Therapeutic agents
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
GB8804016D0 (en) * 1988-02-22 1988-03-23 Boots Co Plc Therapeutic agents
AU2345192A (en) * 1992-07-21 1994-02-14 Boots Company Plc, The Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris

Also Published As

Publication number Publication date
AU5509099A (en) 2000-02-28
CA2339484A1 (fr) 2000-02-17
EP1107759A1 (fr) 2001-06-20
WO2000007595A1 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
CA2226784C (fr) Utilisation d'inhibiteurs de phosphodiesterase specifique de gmpc dans le traitement de l'impuissance
RU2373938C2 (ru) Пиразилпиримидиноны для лечения импотенции
US6300335B1 (en) 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
JP2005502643A (ja) 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用
CZ20023078A3 (cs) Použití pyrido[3,2-E]-pyrazinonů jakožto inhibitorů fosfodiesterasy 5 pro léčbu erektilní dysfunkce
JP2002522388A (ja) 性機能障害の治療のためのピリジノン
AU749703B2 (en) Combination therapy for modulating the human sexual response
CZ20012627A3 (cs) Pouľití imidazo [1,5-a] pyrido [3,2-e]pyrazinonů jako léčiva
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
CA1054521A (fr) Substance biologique
Kim Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey
JP3276762B2 (ja) イソキノリン誘導体を含有する医薬組成物
MXPA01001263A (en) Pyridinones for the treatment of sexual dysfunction
JP3940290B2 (ja) 新規化合物
US20100311785A1 (en) Combination Therapy For Modulating The Human Sexual Response
KR20020095469A (ko) 발기부전을 치료하기 위한, 피리도[3,2-ｅ]-피라지논의포스포디에스테라제 5의 억제제로서의 용도
MXPA01007380A (en) Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
JP2002154962A (ja) イソキノリン誘導体を含有する抗鬱、抗不安剤
MXPA99010400A (en) Combination therapy for modulating the human sexual response